SCHEMBL2832054

SCHEMBL2832054

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2nccc(N3CCC(c4ccccc4)(N(C)C)CC3)n2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CASP3 P42574 10/20 0.37
CASP7 P55210 5/20 0.37
CASP1 P29466 2/20 0.37
CASP6 P55212 2/20 0.37
CASP2 P42575 1/20 0.37
CASP4 P49662 1/20 0.37
CASP9 P55211 1/20 0.37
CASP8 Q14790 1/20 0.37
OPRM1 P35372 6/20 0.35
OPRL1 P41146 5/20 0.35
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833717 0.90 CASP3 (0.37) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2837371 0.89 CASP3 (0.34) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2832118 0.88 CASP3 (0.38) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2834617 0.86 CASP3 (0.34) CASP3CASP7CASP1CASP6CASP2
SCHEMBL2831136 0.85 LMNA (0.42) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2837026 0.85 HTR7 (0.33) CASP3CASP7CASP1CASP6CASP2
SCHEMBL2836668 0.85 ALDH1A1 (0.40) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2836513 0.85 CASP3 (0.34) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2835479 0.85 KDM4E (0.41) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2835829 0.85 CASP3 (0.36) CASP3CASP7CASP1CASP6CASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS KDM4E 3383/4885ALDH1A1 2375/4885LMNA 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.